UNSPSC 51111839: Calusterone

This classification denotes a therapeutic androgen and anabolic steroid with the molecular formula C21H32O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0678G6Q58A, chemically known as 17beta-hydroxy-7beta,17-dimethylandrost-4-en-3-one but generally known as calusterone, which bears US NIH Compound Identifier 28204. European Medicines Agency schedules Calusterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06060MIG.

UNSPSC 51111839 Calusterone, a Commodity code, encompasses anabolic steroid pharmaceuticals supplied through state and local government cooperative purchasing vehicles. Based on recent solicitation activity, state and local buyers procure calusterone and related generic multi-source pharmaceuticals through coordinated purchasing alliances that consolidate demand across multiple jurisdictions and establish master supply agreements with authorized pharmaceutical wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body currently active under this code, leveraging cooperative purchasing to distribute products across participating state and local government facilities in multiple states including Oregon. Vendors supplying under this code must maintain current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA) and FDA requirements, hold contractual relationships with at least two of three designated authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), and carry comprehensive insurance including $5,000,000 commercial general liability and $2,000,000 each in network security and professional liability coverage.

MMCAP's activity centers on the upper Midwest and Pacific Northwest, with the Minnesota Department of Administration coordinating across Oregon and other member states. The most recent opportunity is MMCAP's Request for Proposal S1070000015802 for Generic Multi-Source Pharmaceuticals and OTC Products, posted January 20, 2026, with proposals due March 26, 2026 and a question cutoff of February 18, 2026. Evaluation weighs price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Awarded vendors will be provided to wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026 for an initial two-year term, and performance penalties range from $200 to $1,500 per violation for reporting delays, missed onboarding timelines, or improper class-of-trade denials. No specific dollar values or set-aside designations are disclosed in available documentation.